ALS Germany | ALS Poland | ALS Sweden | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
N | M | SD | N | M | SD | N | M | SD | p-value | post-hoc tests | |
disease duration (months) | 137 | 22.91 | 26.34 | 115 | 26.77 | 11.37 | 51 | 34.61 | 14.14 | < 0.001 | SE > PL > DE |
time since diagnosis (months) | 137 | 11.04 | 12.40 | 115 | 11.63 | 7.13 | 51 | 17.82 | 9.00 | < 0.001 | SE > PL = DE |
ALSFRS-R | 137 | 34.48 | 34.39 | 115 | 34.87 | 8.09 | 51 | 33.04 | 6.42 | 0.375 | |
Progression rate + | 137 | 0.69 | 0.48 | 115 | 0.65 | 0.52 | 51 | 0.52 | 0.37 | 0.098 | |
N (total) | N | % | N (total) | N | % | N (total) | N | % | p-value | post-hoc tests | |
bulbar (vs. spinal) onset | 140 | 40 | 28.6 | 117 | 27 | 23.1 | 53 | 13 | 24.5 | 0.589 | |
PEG/RIG | 140 | 17 | 12.1 | 116 | 6 | 5.2 | 53 | 13 | 24.5 | 0.001 | SE > PL |
NIV | 140 | 50 | 35.7 | 116 | 7 | 6.0 | 53 | 13 | 24.5 | < 0.001 | SE = DE > PL |